Medicine Matters diabetes

Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on September 8, 2017.

Listen to CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on August 8, 2017.

Kevin Fernando, GP Partner at the North Berwick Health Centre near Edinburgh, UK, talks to medwireNews about the importance of the CREDENCE trial from a primary care perspective.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on April 17, 2019.

Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on April 15, 2019.

Editorial Board member Lori Berard talks through the stages and challenges associated with preparing type 2 diabetes patients for insulin therapy.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on June 6, 2018.